Evidence map›Paper›PMID 42111825›Full record

ArticlePeerJ2026

A biomimetic membrane platform for predictive screening and rational engineering of endosomally escaped lipid nanoparticle-CpG oligodeoxynucleotides delivery systems.

Wenyan Cui, Yongjian Cheng, Wenzhong Chen, Behloul Nouredine, Jing He, Yan Zuo, Yue Yang

Abstract read
In one paragraph

Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wenyan CuiDepartment of Pharmaceutical Analysis and R&D, Nanjing Geneleap Biotechnology Co., Ltd., Nanjing, Jiangsu, China.
Yongjian ChengDepartment of Pharmaceutical Analysis and R&D, Nanjing Geneleap Biotechnology Co., Ltd., Nanjing, Jiangsu, China.
Wenzhong ChenDepartment of Pharmaceutical Analysis and R&D, Nanjing Geneleap Biotechnology Co., Ltd., Nanjing, Jiangsu, China.
Behloul NouredineDepartment of Pharmaceutical Analysis and R&D, Nanjing Geneleap Biotechnology Co., Ltd., Nanjing, Jiangsu, China.
Jing HeDepartment of Pharmaceutical Analysis and R&D, Nanjing Geneleap Biotechnology Co., Ltd., Nanjing, Jiangsu, China.
Yan ZuoDepartment of Pharmaceutical Analysis and R&D, Nanjing Geneleap Biotechnology Co., Ltd., Nanjing, Jiangsu, China.
Yue YangDepartment of Pharmaceutical Analysis and R&D, Nanjing Geneleap Biotechnology Co., Ltd., Nanjing, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficient delivery of CpG oligodeoxynucleotides (CpG ODN) adjuvants is constrained by the limited endosomal escape capability of lipid nanoparticles (LNPs). To evaluate this critical parameter, we constructed an

Indexed as

Biomimetic MaterialsEndosomesNanoparticlesOligodeoxyribonucleotidesHumansHydrogen-Ion ConcentrationLipidsLiposomesToll-Like Receptor 9CPG-oligonucleotideLipid NanoparticlesLipidsLiposomesOligodeoxyribonucleotidesToll-Like Receptor 9Biomimetic membraneDelivery system optimizationEndosomal escapeLNP-CpG ODNTLR9

Identifiers

PMID42111825
PMCPMC13155235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.